Pharmaceutical

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for…

2 months ago

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for…

2 months ago

AIML Subsidiary NeuralCloud Solutions Commencing Pilot with Canadian Cardiology Clinic to Advance AI-Powered ECG Reporting

NeuralCloud Solutions to deploy its CardioYield™ platform in a multi-stage pilot program with a full-service cardiology clinic in Canada.Enhance Holter…

2 months ago

CBD Life Sciences Inc. (CBDL) Launches First-of-Its-Kind Mushroom-Infused “Dubai Chocolate Bar”

Dubai's luxury chocolate market-valued at over $1.5 billion and growing 6.8% annually-meets the $35 billion global mushroom supplement boom, creating…

2 months ago

Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology

The 2026 Award is focused on research in paediatric oncology, specifically sarcomasPaediatric sarcomas are among the leading causes of cancer-related…

2 months ago

Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

Three Independent Studies Published in “Alzheimer’s Research & Therapy,” “Journal of Alzheimer’s Disease,” and “Radiology” Validate Nexalin’s Non-Invasive Approach with…

2 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO)…

2 months ago

Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical…

2 months ago

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to…

2 months ago

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously…

2 months ago